Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
Prexasertib is a Second-generation CHK1 Inhibitor for Ovarian Cancer ...
Schematic representation of the effect of prexasertib on leukemic blast ...
Prexasertib (LY2606368) | Anti-tumor | Apoptosis | TargetMol
The low-dose CHK1 inhibitor prexasertib triggers VDAC1 ...
CNS penetration and pharmacodynamics of the CHK1 inhibitor prexasertib ...
Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor ...
Prexasertib dimesylate (LY2606368 dimesylate) | CHK1 Inhibitor ...
Prexasertib Chk1/Chk2抑制剂|CAS 1234015-52-1
Inhibition of Chk1 with Prexasertib Enhances the Anticancer Activity of ...
Prexasertib a cell cycle checkpoint kinases 1 and 2 inhibitor increases ...
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High ...
Chk2 inhibition using prexasertib prevents RGC apoptosis and stimulates ...
Inhibition of Chk2 using prexasertib promotes functional recovery after ...
Dose‐finding study of the checkpoint kinase 1 inhibitor, prexasertib ...
Prexasertib monotherapy elicits superior antitumor responses to ...
Prexasertib LY2606368 靶向药 - 癌症123
Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild ...
Population pharmacokinetic (PK) model–predicted monotherapy prexasertib ...
MYCN amplification induces sensitivity to prexasertib treatment in 11q ...
Continuous manufacturing production route for prexasertib | Download ...
(PDF) The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in ...
(PDF) The CHK1 inhibitor prexasertib in BRCA wild-type platinum ...
Prexasertib HCl (LY2606368) | Chk 抑制剂 | 现货供应 | 美国品牌 | 免费采购电话400-668-6834
Prexasertib (LY2606368, ACR-368) | CHK1 inhibitor | Probechem Biochemicals
Twenty-four-hour delayed treatment with prexasertib is equally as ...
Effect of prexasertib, navitoclax, and prexasertib + navitoclax on ...
Combination treatment with prexasertib and samotolisib increases DNA ...
Prexasertib works in select patients with recur... | MIMS MY
3D and 2D interaction profiles of L31 (a, b) and prexasertib (c, d ...
Effect of prexasertib on cell viability, induction of apoptosis ...
EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in ...
Prexasertib (LY2606368) | ≥99%(HPLC) | Selleck | Chk 阻害剤
Erlotinib co-exposure with prexasertib reduced BAD phosphorylation ...
Prexasertib (LY2606368) | CHK1 Inhibitor | MedChemExpress
Combination of prexasertib with samotolisib increases inhibition of ...
Prexasertib 2HCl (LY2606368 dihydrochloride) | ATP-competitive CHK1 ...
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant ...
Prexasertib HCl (LY2606368) | ≥99%(HPLC) | Selleck | Chk inhibitor QCFile
Prexasertib clinical trial progress and patents: Drug pipeline profiles ...
Prexasertib activates PARP cleavage in primary patient-derived ...
Preclinical efficacy of prexasertib in acute lymphoblastic leukemia - PMC
Prexasertib | CAS:1234015-52-1 | Ark Pharma Scientific Limited
Frontiers | The CHK1 inhibitor Prexasertib is effective against in ...
Combination of prexasertib and adavosertib enhances DNA breaks and ...
a Cell cycle profile of MDAMB231 cells treated with 250 nM prexasertib ...
Resistance to the CHK1 inhibitor prexasertib involves functionally ...
Prexasertib lactate (LY2606368 lactate) | CHK1 Inhibitor | MedChemExpress
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of ...
| The CHK inhibitor, prexasertib, is cytotoxic to MYBL2 High lung ...
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA ...
(PDF) Prexasertib: an investigational checkpoint kinase inhibitor for ...
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor ...
Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor ...
Broad spectrum activity of the checkpoint kinase 1 inhibitor ...
(PDF) Prexasertib, a checkpoint kinase inhibitor: from preclinical data ...
Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune ...
Figure 1 from Development and validation of a sensitive LC MS/MS method ...
BLM overexpression as a predictive biomarker for CHK1 inhibitor ...
A phase Ib study of prexasertib, a checkpoint kinase (CHK1) inhibitor ...
Analysis of Resistance Mechanisms in NSCLC to the Checkpoint Inhibitor ...
CHK1 inhibition combined with SN-38 treatment demonstrates additive ...
A pan-cancer transcriptome analysis identifies replication fork and ...
CHEK1 is a synthetic lethal interactor of FBXO7 in colonic epithelial ...
Sensitivity of TNBC cell lines to CHK1 inhibitor prexasertib. IC50 ...
CHK1 inhibitor induced PARylation by targeting PARG causes excessive ...
LOGO
Prexasertib-induced changes in adaptive immunity. Paired pre-treatment ...
Inhibition of Chk2 promotes neuroprotection, axon regeneration, and ...
30009-3/asset/e607eabd-782e-4ea2-9d4b-f2e55c27a1c5/main.assets/gr3_lrg.jpg)
30009-3/asset/d271b84e-52e0-47e0-8b85-315e4adb11cd/main.assets/gr2.jpg)
